Combiotic™ Platform

Combiotic™ is not an antibiotic. It is a proprietary antimicrobial technology. Traditional antibiotics are typically single agents with limited functions, usually targeting one or a limited number of bacterial pathways. Over time, bacteria can develop resistance to these drugs, reducing their long-term effectiveness. Combiotic™ is different because it is designed to act through multiple complementary mechanisms, including disruption of bacterial membranes, interference with microbial stress-response systems, and antibiofilm activity. This multi-target approach may reduce the likelihood of resistance development compared with conventional single-target antibiotics. Our published research and laboratory studies support its antimicrobial profile and multi-target activity. In addition, we have observed no recurrence in clinical cases treated with our technology, whereas recurrence occurred multiple times in the same patients during previous Standard of Care (SOC) treatment.

Combiotic™ is designed to target microorganisms through multiple mechanisms. Our multi-omics studies and probe-based assays suggest that the plant-derived active agents first interact with the bacterial cell membrane. Bacterial membranes are structurally different from human cell membranes, which helps explain the selective antimicrobial activity observed in our studies.

The inorganic salt component supports this activity by affecting several key bacterial stress and survival pathways, including homeostasis, reactive oxygen species response, energy metabolism, and membrane integrity. This multi-target approach helps explain Combiotic™’s broad antimicrobial and antibiofilm activity.

Laboratory and third-party studies suggest that components of Combiotic™ can support cellular antioxidant, anti-inflammatory, and stress-response pathways by increasing glutathione levels. Glutathione is a naturally occurring antioxidant involved in maintaining cellular redox balance, protecting against oxidative stress, anti-inflammation, and supporting normal immune and cellular function.

This is important in wound care because chronic wounds are often associated with inflammation and oxidative stress, which impairs healing. By supporting cellular protection pathways, Combiotic™ appears to help create a more favourable wound-healing environment.

Our studies suggest that the plant-derived agents in the formulation can increase glutathione, one of the body’s key antioxidant molecules. Glutathione helps protect cells from oxidative stress, which is one of the factors that can delay wound healing.

This antioxidant-supportive effect is one of the features that differentiates Combiotic™ from traditional antimicrobials that primarily focus only on killing bacteria.

Traditional antibiotics are normally single agents with limited functions, usually targeting one or a limited number of bacterial pathways. Over time, bacteria can develop resistance to these drugs, reducing their long-term effectiveness.

Combiotic™ is different because it is designed to act through multiple mechanisms at the same time, including disruption of bacterial membranes, interference with microbial stress-response systems, and antibiofilm activity. This multi-target approach reduces the likelihood of resistance development compared with conventional single-target antibiotics. Our published research and laboratory studies support this multi-target mechanism and antimicrobial profile. Following these, we have clinical cases that have shown non-recurrence with our technology. Recurrence happened several times with Standard of Care treatment in the same patient.

Yes. In laboratory studies, Combiotic™ has shown activity against mixed microbial communities, including Gram-positive bacteria, Gram-negative bacteria, and fungi in both planktonic and biofilm-associated forms.

This is important because chronic and complex wounds often contain mixed microbial populations rather than a single organism. Mixed infections are harder to treat and can contribute to delayed healing, recurrence, and higher healthcare costs.

Biofilms are protective communities of microorganisms surrounded by a self-produced and protective extracellular matrix (EPS). This matrix acts like a shield, making it difficult for antibiotics, antiseptics, and the immune system to reach and eliminate the microbes inside.

Biofilms are especially important in chronic wounds because they can delay healing, increase inflammation, and contribute to persistent or recurring infection. Many chronic wounds contain biofilm-associated bacteria, which is one reason they are difficult to manage with standard treatments.

Combiotic™ is designed to address both the biofilm barrier and the microorganisms protected inside it. The formulation includes safe, carefully selected surfactants that help disrupt the extracellular polymeric substance, or EPS, which forms the protective biofilm matrix.

Once the biofilm structure is disrupted, the antimicrobial components can more effectively interact with the exposed microorganisms. Because Combiotic™ targets multiple microbial pathways, it is designed to rapidly reduce biofilm burden while supporting a safer wound-care environment.

Yes. Laboratory studies have shown activity against antibiotic-resistant microorganisms. Because Combiotic™ uses a multi-target, non-antibiotic antimicrobial approach, it may be useful in settings where resistance to conventional antibiotics is a concern.

Antibiotic-resistant bacteria often survive by avoiding or modifying the specific pathway targeted by an antibiotic. Combiotic™ is different because it affects multiple microbial structures and survival pathways at the same time.

This multi-mechanism activity makes it more difficult for microorganisms to adapt through a single resistance pathway. This is one reason Combiotic™ is being developed as a next-generation approach for infection control and biofilm-associated conditions.

No. Wound care is our lead commercial focus, but Combiotic™ is a broader antimicrobial platform. MHCombiotic is also developing additional applications, including a respiratory infection pipeline that has shown promising results in preclinical studies.

Our long-term goal is to apply the Combiotic™ platform across multiple high-need areas where antimicrobial resistance, biofilms, and inflammation create major treatment challenges.

MHCombiotic has conducted extensive safety testing through internal studies and independent third-party laboratories. Our wound-care products have been developed with safety as a core design principle, using selected ingredients at carefully controlled concentrations.

For topical wound-care applications, the formulation has been evaluated for biocompatibility, irritation, sensitization, systemic toxicity, and repeated-use safety. These studies support the safety profile of the technology for its intended use.

For our topical wound-care products, Combiotic™ is designed to act locally at the wound surface. At the concentrations used in our formulations, the product is not intended to deliver systemic antimicrobial exposure. Systemic toxicity testing has been completed to support the safety profile, but the wound-care products are intended for local topical use at the wound surface.

The Combiotic™ wound-care platform is designed to be antimicrobial while remaining compatible with healthy tissue. Our studies suggest that the formulation supports cell viability and helps maintain a favourable wound environment.

Rather than damaging healthy tissue, the goal of the technology is to reduce microbial burden, disrupt biofilm, and support conditions that allow the body’s normal healing process to progress more effectively.

Yes. Combiotic™ was developed through extensive scientific research, including formulation screening, antimicrobial testing, antibiofilm assays, mechanistic studies, multi-omics systems biology analysis, preclinical safety testing, and third-party laboratory evaluations.

The technology has also been developed in collaboration with experienced scientists and advisors in microbiology, biofilms, antimicrobial resistance, wound care, and medical product development.

Plant-derived molecules can offer strong antimicrobial and anti-inflammatory potential, but crude plant extracts may vary depending on the source, growing conditions, temperature, harvesting, and processing. To improve consistency and reproducibility, MHCombiotic uses highly purified active compounds rather than crude extracts.

Inorganic salts have a long history of use in antimicrobial and wound-care applications, but some metal-based antimicrobial agents can raise toxicity concerns at higher concentrations. By combining purified plant-derived molecules with inorganic salts in a synergistic formulation, Combiotic™ is designed to maintain strong antimicrobial activity while using much lower concentrations of individual active components.

This approach supports consistency, efficacy, safety, and scalability.

Antimicrobial resistance, or AMR, occurs when microorganisms evolve and become harder to kill with existing antimicrobial treatments. This can lead to longer infections, delayed healing, higher treatment costs, and increased risk of serious complications.

In wound care, AMR is especially concerning because chronic wounds can become long-term reservoirs for resistant bacteria and biofilms. If infection spreads, patients may face hospitalization, surgery, sepsis, or even amputation.

MHCombiotic is developing non-traditional antimicrobial technologies to help reduce reliance on conventional antibiotics and address the growing challenge of AMR.

MHCombiotic designed its technology specifically for the wound environment. Instead of testing only under standard laboratory conditions, we developed and screened formulations in conditions that better mimic the complex environment of wounds.

This includes evaluating performance in simulated wound fluid, biofilm models, mixed microbial communities, and safety-focused cell-based systems. We also conducted mechanistic studies to understand how the technology works and how it can be optimized to improve patient outcomes while reducing side effects.

Our approach combines antimicrobial activity, antibiofilm performance, safety, and wound-healing support in one integrated platform.

Yes. Combiotic™ is designed using selected plant-derived small molecules and carefully selected controlled inorganic components. The result is environmentally safe compounds. The formulation strategy aims to reduce reliance on conventional antibiotics, lower unnecessary chemical burden, and use effective concentrations of active ingredients more efficiently.

By improving antimicrobial performance through synergy, the technology may reduce the amount of active material needed while supporting safer and more sustainable infection-control solutions.

We have not done a specific wound-charge study yet, so we cannot claim that Combiotic™ directly changes wound charge. Based on the formulation, we believe it may interact indirectly with charged components in chronic wounds, such as biofilm matrix, bacterial membranes, proteins, salts, and exudate.